retatrutide liver Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming Retatrutide UK 2026: Phase 3

Food and Drug Administration (FDA) approved semaglutide for obesity management, marking a new milestone in the application of GLP-1RAs for weight loss (Jordan et al., 2024)

Measurement of glucose uptake in adipocyte cells treated under various conditions using Glucose Uptake-Glo Assay

Water Instead of Diet Drinks Associated With Two-Fold Rate of Diabetes Remission in Women

18 612 months: Sustained hormone improvements

Diabetes Metab J 44(6):80218 Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS et al (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept